THE MCMANUS GROUP for GILEAD SCIENCES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Funding for HCV and public health activities via appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Health Issues HCR
Pharmaceutical policy as it relates to payments under the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Medicare/Medicaid MMM
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412). S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.